Advances in multimodal treatment for stage IIIA-N2 non-small cell lung cancer

In Stage IIIA-N2 non-small cell lung cancer (NSCLC), the accuracy of combined positron-emission tomography/computed tomography imaging (PET-CT), together with mediastinal staging techniques, has led to a wide range of challenging clinical scenarios in terms of therapeutic management. Concurrent chem...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical and translational research 2021-04, Vol.7 (2), p.185-198
Main Authors: Montemuiño Muñiz, Sara, Marcos Sánchez, Soraya, Calzas Rodríguez, Julia, Losada Vila, Beatriz, Llorente Herrero, Esther, Hisado Díaz, María Dolores, Valeri-Busto González, Victoria, Taboada Valladares, Begoña, Vaquero Barrón, Blanca, Marcos Jimenez, Francisco José, Amor Alonso, Sergio, Moradiellos, Javier, Rodríguez de Dios, Núria, Couñago, Felipe
Format: Article
Language:English
Subjects:
Review
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In Stage IIIA-N2 non-small cell lung cancer (NSCLC), the accuracy of combined positron-emission tomography/computed tomography imaging (PET-CT), together with mediastinal staging techniques, has led to a wide range of challenging clinical scenarios in terms of therapeutic management. Concurrent chemoradiotherapy followed by consolidation immunotherapy remains the standard of care. In patients with potentially-resectable disease, surgery plays an important role in multimodal therapy. The introduction of targeted therapies and immune-checkpoint inhibitors has revolutionized multimodal treatment. In the present article, we review current treatment options and future trends in stage IIIA-N2 NSCLC. This article provides insight into the current status of multimodal treatment for NSCLC to support decision-making in routine clinical practice.
ISSN:2424-810X
2382-6533
2424-810X
DOI:10.18053/jctres.07.202102.013